Palliative Radiotherapy in Patients with a Symptomatic Pelvic Mass of Metastatic Colorectal Cancer

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2011 May 24

PMID 21600018

Citations 14

Authors

Sun Hyun Bae

Won Park

Doo Ho Choi

Heerim Nam

Won Ki Kang

Young Suk Park

Joon Oh Park

Ho Kyung Chun

Woo Yong Lee

Seong Hyeon Yun

Hee Cheol Kim

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the palliative role of radiotherapy (RT) and define the effectiveness of chemotherapy combined with palliative RT (CCRT) in patients with a symptomatic pelvic mass of metastatic colorectal cancer.

Methods: From August 1995 to December 2007, 80 patients with a symptomatic pelvic mass of metastatic colorectal cancer were treated with palliative RT at Samsung Medical Center. Initial presenting symptoms were pain (68 cases), bleeding (18 cases), and obstruction (nine cases). The pelvic mass originated from rectal cancer in 58 patients (73%) and from colon cancer in 22 patients (27%). Initially 72 patients (90%) were treated with surgery, including 64 complete local excisions; 77% in colon cancer and 81% in rectal cancer. The total RT dose ranged 8-60 Gy (median: 36 Gy) with 1.8-8 Gy per fraction. When the α/β for the tumor was assumed to be 10 Gy for the biologically equivalent dose (BED), the median RT dose was 46.8 Gy10 (14.4-78). Twenty one patients (26%) were treated with CCRT. Symptom palliation was assessed one month after the completion of RT.

Results: Symptom palliation was achieved in 80% of the cases. During the median follow-up period of five months (1-44 months), 45% of the cases experienced reappearance of symptoms; the median symptom control duration was five months. Median survival after RT was six months. On univariate analysis, the only significant prognostic factor for symptom control duration was BED ≥40 Gy10 (p < 0.05), and CCRT was a marginally significant factor (p = 0.0644). On multivariate analysis, BED and CCRT were significant prognostic factors for symptom control duration (p < 0.05).

Conclusions: RT was an effective palliation method in patients with a symptomatic pelvic mass of metastatic colorectal cancer. For improvement of symptom control rate and duration, a BED ≥ 40 Gy10 is recommended when possible. Considering the low morbidity and improved symptom palliation, CCRT might be considered in patients with good performance status.

Citing Articles

Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer.

Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M Cancer Med. 2024; 13(9):e7028.

PMID: 38711364 PMC: 11074703. DOI: 10.1002/cam4.7028.

Palliative short-course radiotherapy (RAPASH study) in patients with rectal cancer.

Lupattelli M, Tenti M, Nucciarelli S, Graziosi L, De Angelis V, Fulcheri C Rep Pract Oncol Radiother. 2023; 28(3):309-315.

PMID: 37795394 PMC: 10547409. DOI: 10.5603/RPOR.a2023.0033.

Effect of Abdominal Circumference on the Irradiated Bowel Volume in Pelvic Radiotherapy for Rectal Cancer Patients: Implications for the Radiotherapy-Related Intestinal Toxicity.

Wang G, Wang W, Jin H, Dong H, Chen W, Li X Front Oncol. 2022; 12:843704.

PMID: 35280741 PMC: 8904399. DOI: 10.3389/fonc.2022.843704.

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study.

Zheng S, Wang Y, Liu S, Huang Z, Wang G, Lin J Cancer Cell Int. 2022; 22(1):36.

PMID: 35073926 PMC: 8788066. DOI: 10.1186/s12935-022-02464-7.

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors.

Ji X, Zhao Y, Zhu X, Shen Z, Li A, Chen C Front Oncol. 2021; 10:595781.

PMID: 33585211 PMC: 7878536. DOI: 10.3389/fonc.2020.595781.

References

Pilipshen S, Heilweil M, Quan S, Sternberg S, Enker W . Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer. 1984; 53(6):1354-62. DOI: 10.1002/1097-0142(19840315)53:6<1354::aid-cncr2820530623>3.0.co;2-j. View

Oconnell M, CHILDS D, MOERTEL C, HOLBROOK M, SCHUTT A, Rubin J . A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma. Int J Radiat Oncol Biol Phys. 1982; 8(7):1115-9. DOI: 10.1016/0360-3016(82)90057-8. View

Coia L, Soffen E, Schultheiss T, Martin E, Hanks G . Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer. 1993; 71(2):281-6. DOI: 10.1002/1097-0142(19930115)71:2<281::aid-cncr2820710202>3.0.co;2-0. View

ROMINGER C, Gunderson L, Gelber R, Conner N . Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group study (76-16). Am J Clin Oncol. 1985; 8(2):118-27. DOI: 10.1097/00000421-198504000-00003. View

Willett C, Gunderson L . Palliative treatment of rectal cancer: is radiotherapy alone a good option?. J Gastrointest Surg. 2004; 8(3):277-9. DOI: 10.1016/j.gassur.2003.11.015. View

Phillips R, Hittinger R, Blesovsky L, Fry J, Fielding L . Local recurrence following 'curative' surgery for large bowel cancer: II. The rectum and rectosigmoid. Br J Surg. 1984; 71(1):17-20. DOI: 10.1002/bjs.1800710105. View

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider J . Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1):109-22. DOI: 10.1016/0360-3016(91)90171-y. View

Hayter C, Paszat L, Youssef Y, Shelley W, Schulze K . A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. Radiother Oncol. 2000; 56(3):329-33. DOI: 10.1016/s0167-8140(00)00225-5. View

KLIGERMAN M, Knowlton A . Evaluation of palliative irradiation in rectal carcinoma. Radiology. 1972; 104(3):673-7. DOI: 10.1148/104.3.673. View

10.

Gunderson L, Martenson J . Irradiation of adenocarcinomas of the gastrointestinal tract malignancies. Front Radiat Ther Oncol. 1988; 22:127-48. DOI: 10.1159/000415104. View

11.

Lybeert M, Martijn H, De Neve W, Crommelin M, Ribot J . Radiotherapy for locoregional relapses of rectal carcinoma after initial radical surgery: definite but limited influence on relapse-free survival and survival. Int J Radiat Oncol Biol Phys. 1992; 24(2):241-6. DOI: 10.1016/0360-3016(92)90678-b. View

12.

Kim M, Rana V, Janjan N, Das P, Phan A, Delclos M . Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2007; 47(3):421-7. DOI: 10.1080/02841860701621233. View

13.

WHITELEY Jr H, STEARNS Jr M, LEAMING R, DEDDISH M . Radiation therapy in the palliative management of patients with recurrent cancer of the rectum and colon. Surg Clin North Am. 1969; 49(2):381-7. DOI: 10.1016/s0039-6109(16)38795-3. View

14.

Burmeister B, Denham J, OBrien M, Jamieson G, Gill P, Devitt P . Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys. 1995; 32(4):997-1006. DOI: 10.1016/0360-3016(94)00449-u. View

15.

Cameron S, Hunerbein D, Mansuroglu T, Armbrust T, Scharf J, Schworer H . Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy. BMC Cancer. 2009; 9:218. PMC: 2709904. DOI: 10.1186/1471-2407-9-218. View

16.

Crane C, Janjan N, Abbruzzese J, Curley S, Vauthey J, Sawaf H . Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys. 2001; 49(1):107-16. DOI: 10.1016/s0360-3016(00)00777-x. View

17.

Tey J, Back M, Shakespeare T, Mukherjee R, Lu J, Lee K . The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2006; 67(2):385-8. DOI: 10.1016/j.ijrobp.2006.08.070. View

18.

Douglass Jr H, MOERTEL C, Mayer R, Thomas P, Lindblad A, Mittleman A . Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986; 315(20):1294-5. DOI: 10.1056/NEJM198611133152014. View

19.

Mohiuddin M, Marks G, Marks J . Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer. 2002; 95(5):1144-50. DOI: 10.1002/cncr.10799. View

20.

Harvey J, Bessell J, Beller E, Thomas J, Gotley D, Burmeister B . Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Dis Esophagus. 2004; 17(3):260-5. DOI: 10.1111/j.1442-2050.2004.00420.x. View